Lasting amelioration in the clinical course of decompensated alcoholic cirrhosis with boost infusions of mobilized peripheral blood stem cells
Open accessAbstract
For end-stage liver disease, liver transplantation provides the only definite cure; however, many patients die while in the waiting list for donation. Various stem cell populations have been described to contribute to liver regeneration and there is accumulating evidence for the participation of hematopoietic stem cells (HSCs) in this process. We here report two cases treated with boost infusions of autologous mobilized HSCs to regenerate cirrhotic liver. The procedure was safe and well tolerated. Both patients showed a lasting amelioration in the clinical course of the disease during the 30 months of follow-up. These results suggest that the procedure may be considered in a clinical study setting as a bridging therapy until organ transplantation becomes available or to reverse a decompensated cirrhosis to a compensated one. Additional studies in this area will be required to document efficacy and evaluate toxicity.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Splenomegaly and hypersplenism in patients with cirrhosis may lead to a reduced harvest of stem cells as a consequence of their sequestration in the spleen.
“Splenomegaly and hypersplenism in these patients may also lead to a reduced harvest of stem cells as a consequence of their sequestration in the spleen [67].”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [67]
Administration of G-CSF in patients with splenomegaly, as in those with cirrhosis, poses a theoretical risk of splenic rupture due to the potential for G-CSF to induce spleen enlargement.
“However, the administration of G-CSF in patients with splenomegaly, as those with cirrhosis, poses a theoretical risk of splenic rupture due to the potential for G-CSF to induce spleen enlargement [66, 67].”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [67]
The citation lists haven’t been fetched yet
References 24 · Cited by 101
- Authors
- Yannaki, E., Anagnostopoulos, A., Kapetanos, D., Xagorari, A., Iordanidis, F., Batsis, I., Kaloyannidis, P., Athanasiou, E., Dourvas, G., Kitis, G., & Fassas, A.
- Affiliations
- G. Papanikolaou General Hospital (GR)
- Corresponding author
- Yannaki, Evangelia
- Venue
- Experimental Hematology
- Publisher
- Elsevier BV
- Published
- 2006-11
- Volume
- 34
- Issue
- 11
- Pages
- 1583-1587
- ISSN
- 0301-472X (ISSN-L)
- OpenAlex
- W2088734821
- Cited by
- 101
- References
- 24
- Citations by year
- 2025: 3 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 4 · 2018: 5 · 2017: 3 · 2016: 9 · 2015: 5 · 2014: 9 · 2013: 9 · 2012: 9
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Experimental Hematology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
- Keywords
- alcoholic cirrhosis, decompensated cirrhosis, hematopoietic stem cells, autologous stem cell mobilization, liver regeneration, bridging therapy, liver transplantation, stem cell therapy
- MeSH terms
- Biopsy, Follow-Up Studies, Humans, Immunohistochemistry, Infusions, Intravenous, Liver Cirrhosis, Alcoholic, Male, Middle Aged, Transplantation, Homologous, Treatment Outcome, Recovery of Function, Peripheral Blood Stem Cell Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review